HARP: Harpoon Tx Net earnings per share (EPS TTM)

Harpoon Therapeutics, Inc. (HARP) - corporate logo

Integration into the Merck structure at a premium and the success of the TriTAC platform in treating lung cancer define the financial profile of Harpoon Therapeutics (HARP). The change in the rolling annual EPS clearly demonstrates this trend, where -8.74 becomes the new value for the indicator. A stable liquidity reserve supports the development of targeted drugs, although geopolitical tensions and sanctions complicate the logistics of biomaterials, slowing down global certification.

HARP Harpoon Therapeutics Net earnings per share for the last 12 months (07/04/2022 - 03/16/2024)

Summary analytical data breakdowns for Harpoon Therapeutics Corp (HARP)

Fundamental valuation:HARP - Harpoon Therapeutics Corp
Flagship merchandise of Harpoon Tx

Amidst fierce competition for patients and patent wars within the T-cell immunotherapy sector, this metric allows for an assessment of the financial stability of Harpoon Therapeutics (HARP). Net income per share over the last four quarters is calculated by dividing the total annual net income by the number of securities. This indicator demonstrates the actual efficiency of the business, stripped of the impact of issuance. Positive dynamics confirm management's ability to withstand the expansion of mRNA therapy, while a decline in the indicator signals a risk of capital freeze.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX